Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

16 juil. 2025 13h13 HE | Source: Quetzal Therapeutics

Quetzal Therapeutics Debuts with Expert Leadership, High-Impact Pipeline and $50 Million of Committed Capital

Quetzal Therapeutics, a newly formed biopharmaceutical company, announced its official launch today with $50 million of committed capital.
17 juin 2021 08h30 HE | Source: HelixBind

HelixBind Awarded $3MM NIH Grant to Support Testing of Its RaPID Diagnostic Platform for Invasive Infections Associated with Sepsis

BOXBOROUGH, Mass., June 17, 2021 (GLOBE NEWSWIRE) -- HelixBind, which is developing an innovative diagnostic platform to revolutionize care for invasive infections such as sepsis, announced today it...
24 août 2020 11h47 HE | Source: HelixBind

FDA Grants HelixBind Breakthrough Device Designation for RaPID Sepsis Test

BOXBOROUGH, Mass., Aug. 24, 2020 (GLOBE NEWSWIRE) -- HelixBind, which is developing an innovative diagnostic platform to revolutionize care for invasive infections such as sepsis, announced today it...
16 juil. 2020 12h01 HE | Source: HelixBind

HelixBind Awarded $3MM Grant from NIH for New Rapid Test for the Early Detection of Lyme Disease

BOXBOROUGH, Mass., July 16, 2020 (GLOBE NEWSWIRE) -- HelixBind, which is developing an innovative diagnostic platform to revolutionize care for patients afflicted with invasive microbial infections,...
10 juin 2020 10h29 HE | Source: HelixBind

HelixBind Awarded $3MM Grant from NIH and Expands Clinical Advisory Board to Accelerate Development of Its Diagnostic Platform for Invasive Infections

BOXBOROUGH, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- HelixBind, which is developing an innovative diagnostic platform to revolutionize care for invasive infections such as sepsis, announced today it...